期刊文献+

沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤患者的疗效观察 被引量:7

下载PDF
导出
摘要 目的:观察沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤患者的疗效。方法:选取弥漫大B细胞淋巴瘤患者60例作为研究对象,采取计算机随机抽取法分为对照组和观察组,每组各30例。对照组患者采取CHOP方案化疗;观察组患者在CHOP方案化疗的同时加用沙利度胺治疗。比较两组患者的临床疗效。结果:观察组患者的客观缓解率、完全缓解率分别为83.33%、53.33%,明显高于对照组56.67%、26.67%(P<0.05),观察组患者的不良反应发生率为23.33%,与对照组16.67%比较,差异无统计学意义(P>0.05);观察组患者的3年存活率为76.67%,较对照组50.00%高(P<0.05)。与治疗前相比,治疗后,两组患者的VEGF水平均明显降低(P<0.05),且观察组患者的降低幅度更低(P<0.05)。结论:在弥漫大B细胞淋巴瘤患者的临床治疗中,采取沙利度胺联合CHOP化疗方案治疗效果优于单纯CHOP方案化疗效果。
出处 《中国民康医学》 2016年第21期34-35,共2页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献4

二级参考文献43

  • 1Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103: 275-282. 被引量:1
  • 2Banham AH, Connors JM, Brown P J, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res, 2005, 11: 1065-1072. 被引量:1
  • 3Berglund M, Thunberg U, Amini RM, et al. Evaluation of immu- nophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol, 2005, 18: 1113-1120. 被引量:1
  • 4Veelken H, Vik Dannheim S, Schulte mounting J, et al. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol, 2007, 18: 931-939. 被引量:1
  • 5Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 2009, 15: 5494-5502. 被引量:1
  • 6Oh YH, Park CK. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD 138 expression as a poor prognostic factor. J Korean Med Sci, 2006; 21: 397-405. 被引量:1
  • 7Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res, 2007, 31: 1579-1583. 被引量:1
  • 8van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006.24: 4135-4142. 被引量:1
  • 9Coffier B, Thiebletine C, Van Den Neste, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab- CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116: 2040-2045. 被引量:1
  • 10Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituxirnab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol, 2010, 28: 27-32. 被引量:1

共引文献258

同被引文献50

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部